Cargando…

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma(†)

OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawai, Akira, Araki, Nobuhito, Naito, Yoichi, Ozaki, Toshifumi, Sugiura, Hideshi, Yazawa, Yasuo, Morioka, Hideo, Matsumine, Akihiko, Saito, Kenichi, Asami, Shun, Isu, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943671/ https://www.ncbi.nlm.nih.gov/pubmed/28173193 http://dx.doi.org/10.1093/jjco/hyw175

Ejemplares similares

A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
por: Kawai, Akira, et al.
Publicado: (2016)

Efficacy of Trabectedin in Patients with Advanced Translocation‐Related Sarcomas: Pooled Analysis of Two Phase II Studies
por: Takahashi, Mitsuru, et al.
Publicado: (2017)

Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials
por: Endo, Makoto, et al.
Publicado: (2020)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study
por: Nakamura, Tomoki, et al.
Publicado: (2016)

Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma
por: Morioka, Hideo, et al.
Publicado: (2016)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Validation of radiographic response evaluation criteria of preoperative chemotherapy for bone and soft tissue sarcomas: Japanese Orthopaedic Association Committee on Musculoskeletal Tumors Cooperative Study
por: Ueda, Takafumi, et al.
Publicado: (2008)

Deep infection in tumor endoprosthesis around the knee: a multi-institutional study by the Japanese musculoskeletal oncology group
por: Morii, Takeshi, et al.
Publicado: (2013)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016)

Reconstruction With Ipsilateral Fibula Transfer With Pasteurized Bone After Excision of Bone Sarcoma of the Tibia
por: Ozaki, Toshifumi, et al.
Publicado: (2004)

New practical approach against sarcoma
por: Araki, Nobuhito
Publicado: (2014)

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
por: Thomas, Colin, et al.
Publicado: (2016)

The value of trabectedin in the treatment of soft tissue sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2016)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma
por: De Vita, Alessandro, et al.
Publicado: (2016)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study
por: Fujiwara, Tomohiro, et al.
Publicado: (2022)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells
por: Fujiwara, Tomohiro, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Diagnosis and treatment of Ewing sarcoma of the bone: a review article
por: Ozaki, Toshifumi
Publicado: (2015)

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
por: Imai, Reiko, et al.
Publicado: (2018)

Surgical Treatment for Skeletal Metastases From Soft Tissue Sarcomas: Experience With 23 Lesions in 20 Patients
por: Yoshikawa, Hideki, et al.
Publicado: (1998)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma
por: Ueda, Takafumi, et al.
Publicado: (2014)

Prognostic Value of Relevant Clinicopathologic Variables in Epithelioid Sarcoma: A Multi-Institutional Retrospective Study of 44 Patients
por: Asano, Naofumi, et al.
Publicado: (2015)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas
por: ATSUMI, SATORU, et al.
Publicado: (2013)

Primary intradural extramedullary Ewing sarcoma: A case report and literature review
por: Izubuchi, Yuya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t09hf217oo8s6oo50d06ec0q16